新德里金属β-内酰胺酶产生菌引起的血流感染在区域暴发期间的临床特征及转归
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.
作者信息
Falcone Marco, Tiseo Giusy, Antonelli Alberto, Giordano Cesira, Di Pilato Vincenzo, Bertolucci Pietro, Parisio Eva Maria, Leonildi Alessandro, Aiezza Noemi, Baccani Ilaria, Tagliaferri Enrico, Righi Lorenzo, Forni Silvia, Sani Spartaco, Mechi Maria Teresa, Pieralli Filippo, Barnini Simona, Rossolini Gian Maria, Menichetti Francesco
机构信息
Infectious Disease Unit, Azienda Ospedaliera Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
出版信息
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.
Abstract
Limited data about New Delhi metallo-β-lactamase (NDM) bacteremia are available. Blood isolates from 40 patients with NDM bacteremia were studied for antibiotic susceptibility and whole-genomic sequencing. NDM bacteremia has high 30-day mortality. In most cases, aztreonam-avibactam is active in vitro. Ceftazidime-avibactam plus aztreonam may represent a feasible therapeutic option.
摘要
关于新德里金属β-内酰胺酶（NDM）菌血症的资料有限。对40例NDM菌血症患者的血液分离株进行了抗生素敏感性和全基因组测序研究。NDM菌血症的30天死亡率很高。在大多数情况下，氨曲南-阿维巴坦在体外具有活性。头孢他啶-阿维巴坦加氨曲南可能是一种可行的治疗选择。
相似文献
1
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.新德里金属β-内酰胺酶产生菌引起的血流感染在区域暴发期间的临床特征及转归
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.
2
A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam.1例由携带新德里金属β-内酰胺酶（NDM）的塞德莱克枸橼酸杆菌引起的骨髓炎经头孢他啶-阿维巴坦和氨曲南成功治疗的病例
Cureus. 2022 Sep 6;14(9):e28855. doi: 10.7759/cureus.28855. eCollection 2022 Sep.
3
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展：体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
4
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.氨曲南联合克拉维酸、他唑巴坦或阿维巴坦治疗产金属β-内酰胺酶革兰氏阴性菌感染。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00010-19. Print 2019 May.
5
Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing .病例报告：通过弹性输液器联合持续输注头孢他啶-阿维巴坦和氨曲南12周，用于治疗由产金属β-内酰胺酶菌引起的骨和关节感染。
Front Med (Lausanne). 2023 Aug 3;10:1224922. doi: 10.3389/fmed.2023.1224922. eCollection 2023.
6
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间，作为国际最佳耐药监测网络（INFORM）全球监测项目的一部分，分离出携带 OXA-48 酶的肠杆菌科细菌，对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
7
Ceftazidime-avibactam use for the treatment of OXA-48- and/or New Delhi metallo-β-lactamase-producing in cancer patients: a retrospective observational study.头孢他啶-阿维巴坦治疗癌症患者中产 OXA-48-和/或新德里金属β-内酰胺酶的应用：一项回顾性观察研究。
Ann Saudi Med. 2023 Nov-Dec;43(6):373-379. doi: 10.5144/0256-4947.2023.373. Epub 2023 Dec 7.
8
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.在一家主要癌症中心的肠杆菌科血流感染中，发现头孢他啶-阿维巴坦的非敏感性率较高，并鉴定出新型德里金属β-内酰胺酶的产生。
Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.
9
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
10
Successful treatment of ceftazidime/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report.头孢他啶/阿维巴坦联合氨曲南成功治疗1例自体造血干细胞移植期间粒细胞缺乏的NK/T淋巴瘤患者血流感染及肠道感染产NDM肺炎克雷伯菌：病例报告
Eur J Clin Microbiol Infect Dis. 2022 Nov 12:1-4. doi: 10.1007/s10096-022-04523-3.
引用本文的文献
1
AMRrounds: susceptibility to the new tetracycline-derivative eravacycline of New Delhi metallo-β-lactamase-producing complex.抗菌药物耐药性讨论：产新德里金属β-内酰胺酶菌株对新型四环素衍生物依拉环素的敏感性
JAC Antimicrob Resist. 2025 Aug 28;7(4):dlaf153. doi: 10.1093/jacamr/dlaf153. eCollection 2025 Aug.
2
Impact of multidrug resistance in cancer patients with bloodstream infections caused by Gram-negative bacilli: results from a multicentre study.多重耐药对革兰氏阴性杆菌所致血流感染癌症患者的影响：一项多中心研究结果
JAC Antimicrob Resist. 2025 Jul 4;7(4):dlaf116. doi: 10.1093/jacamr/dlaf116. eCollection 2025 Aug.
3
Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study.八个低收入和中等收入国家碳青霉烯类耐药革兰氏阴性菌感染估计治疗不足情况：一项建模研究
Lancet Infect Dis. 2025 Sep;25(9):1011-1019. doi: 10.1016/S1473-3099(25)00108-2. Epub 2025 Apr 30.
4
Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms.采用联合抗菌方案的靶向“敲除”疗法为广泛耐药的产碳青霉烯酶微生物的管理恢复了治疗选择。
J Med Microbiol. 2025 Apr;74(4). doi: 10.1099/jmm.0.002007.
5
Aerobic bacteria study, clinical spectrum, and outcome of patients with community-acquired multidrug-resistant pathogens.社区获得性多重耐药病原体患者的需氧菌研究、临床谱及转归
J Family Med Prim Care. 2024 Nov;13(11):5052-5059. doi: 10.4103/jfmpc.jfmpc_680_24. Epub 2024 Nov 18.
6
Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?应对产金属β-内酰胺酶革兰氏阴性菌感染的当前治疗格局：存在哪些局限性？
Infect Dis Ther. 2024 Nov;13(11):2423-2447. doi: 10.1007/s40121-024-01044-8. Epub 2024 Oct 1.
7
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against isolates.评估肉汤纸片洗脱法测定头孢他啶/阿维巴坦联合氨曲南对 分离株的药敏结果。
Microbiol Spectr. 2024 Oct 3;12(10):e0095324. doi: 10.1128/spectrum.00953-24. Epub 2024 Sep 3.
8
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.并非所有耐碳青霉烯铜绿假单胞菌菌株都相同：根据耐药机制调整抗生素治疗。
Curr Opin Infect Dis. 2024 Dec 1;37(6):594-601. doi: 10.1097/QCO.0000000000001044. Epub 2024 Sep 18.
9
Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive MBL+, NDM+ [Letter].头孢他啶-阿维巴坦与氨曲南对产碳青霉烯酶的MBL+、NDM+菌的协同作用[信函]
Infect Drug Resist. 2024 Jul 15;17:3035-3036. doi: 10.2147/IDR.S433652. eCollection 2024.
10
Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.碳青霉烯类耐药肠杆菌科血流感染的死亡因素和抗生素选择：具有同时存在的 NDM-1 和 OXA-48 的高流行地区的相关见解。
Clin Transl Sci. 2024 Jun;17(6):e13855. doi: 10.1111/cts.13855.
本文引用的文献
1
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.监测头孢他啶-阿维巴坦和氨曲南在治疗一株携带肺炎克雷伯菌碳青霉烯酶 4 型和新德里金属β-内酰胺酶 1 型的多药耐药肠杆菌引起的血流感染中的浓度。
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
2
Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae.产新德里金属β-内酰胺酶（NDM-1）肠杆菌科血流感染的危险因素和流行病学预测因素。
Epidemiol Infect. 2019 Jan;147:e137. doi: 10.1017/S0950268819000256.
3
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.在医疗环境中 NDM 型金属β-内酰胺酶及其细菌生产者
Clin Microbiol Rev. 2019 Jan 30;32(2). doi: 10.1128/CMR.00115-18. Print 2019 Mar 20.
4
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
5
Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016.2016年，意大利，ST16型肺炎克雷伯菌同时产生NDM-1和OXA-232。
Future Microbiol. 2017 Oct;12:1119-1122. doi: 10.2217/fmb-2017-0041. Epub 2017 Sep 6.
6
New Delhi Metallo-Beta-Lactamase (NDM-1)-Producing Klebsiella Pneumoniae Isolated from a Burned Patient.从一名烧伤患者身上分离出的产新德里金属β-内酰胺酶（NDM-1）的肺炎克雷伯菌。
Am J Case Rep. 2017 Jul 18;18:805-809. doi: 10.12659/ajcr.903992.
7
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.头孢他啶-阿维巴坦与氨曲南：克服肠杆菌科细菌和铜绿假单胞菌中金属β-内酰胺酶介导的β-内酰胺耐药性的有趣策略
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01008-17. Print 2017 Sep.
8
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
9
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.头孢他啶/阿维巴坦聚焦：耐多药革兰氏阴性菌感染的新选择。
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
10
Performance of the BD MAX™ instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae.在产碳青霉烯酶肠杆菌科细菌呈地方性传播的环境中，使用BD MAX™仪器和Check-Direct CPE实时荧光定量PCR检测直肠拭子中碳青霉烯酶基因的性能。
Diagn Microbiol Infect Dis. 2016 Sep;86(1):30-4. doi: 10.1016/j.diagmicrobio.2016.06.002. Epub 2016 Jun 7.
Zotero 插件